Les marqueurs biologiques de l’inflammation : faisons le point.

Biomarkers; CRP; Infection; Multiplex; Procalcitonin; Inflammation; Calcitonin; C-Reactive Protein; Blood Sedimentation; C-Reactive Protein/analysis; C-Reactive Protein/metabolism; Humans; Inflammation/diagnosis

Abstract :

[en] Biomarkers of inflammation such as sedimentation rate, C-reactive protein and procalcitonin are used in daily clinical practice for the diagnosis, prognosis and follow-up of patients with fever or inflammatory syndrome. The purpose of this article is to summarize the current knowledge about these main biological tests and to discuss new biomarkers and new assay approaches such as multiplex technology.
[fr] : Le dosage des biomarqueurs de l’inflammation, tels que la vitesse de sédimentation, la protéine-C réactive et la procalcitonine, est utilisé quotidiennement dans le cadre du diagnostic, du pronostic et du suivi des patients fébriles ou souffrant de syndrome inflammatoire. Le but de cet article est de résumer les connaissances actuelles quant à ces principaux tests biologiques et d’aborder les nouveaux biomarqueurs ainsi que les nouvelles approches de dosage comme la technologie multiplex.

Disciplines :

Immunology & infectious disease

Author, co-author :

LE GOFF, Caroline ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chimie clinique

LADANG, Aurélie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chimie clinique

GOTHOT, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie biologique et immuno-hématologie

CAVALIER, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > > Service de chimie clinique

Language :

French

Title :

Les marqueurs biologiques de l’inflammation : faisons le point.

Alternative titles :

[en] Biological markers of inflammation : an update.

Publication date :

May 2022

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Be

Volume :

Issue :

5-6

Pages :

258-264

Peer reviewed :

Editorial Reviewed verified by ORBi

Available on ORBi :

since 23 February 2023

Statistics

Number of views

319 (8 by ULiège)

Number of downloads

6367 (14 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Liagre B, Léger D, Vergne-Salle P. Exploration biochimique de l’inflammation. In Bonnefont-Rousselot D, Beaudeux J-L, Charpiot P, Editors. Explorations en biochimie medicale: interprétations et orientations diagnostiques. 1st ed. Paris: Lavoisier;2019. p.221-230.
Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 1999;7:169-77.
Monti M. Vieux et nouveaux biomarqueurs inflammatoires: Quelle utilité pour l’interniste généraliste ? Rev Med Suisse 2013;9:2008-12.
Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982;389:39-48.
Gauldie J, Richards C, Harnish D, et al. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987;84:7251-5.
Boras E, Slevin M, Alexander MY, et al. Monomeric C-reactive protein and Notch-3 co-operatively increase angiogenesis through PI3K signalling pathway. Cytokine 2014;69:165-79.
Chenillot O, Henny J, Steinmetz J, et al. High sensitivity C-reactive protein: biological variations and reference limits. Clin Chem Lab Med 2000;38:1003-11.
Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol 2018;9:754.
Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004;279:48487-90.
Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109:II2-10.
Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001;38:189-97.
Gursoy AY, Caglar GS, Kiseli M, et al. CRP at early follicular phase of menstrual cycle can cause misinterpretation for cardiovascular risk assessment. Interv Med Appl Sci 2015;7:143-6.
Carobene A, Aarsand AK, Guerra E, et al. European Biological Variation Study (EUBIVAS): within- and between-subject biological variation data for 15 frequently measured proteins. Clin Chem 2019;65:1031-41.
Nunes LA, Brenzikofer R, de Macedo DV. Reference change values of blood analytes from physically active subjects. Eur J Appl Physiol 2010;110:191-8.
Hage FG, Szalai AJ. C-reactive protein gene polymorphisms, c-reactive protein blood levels, and cardiovascular disease risk. J Am Coll Cardiol 2007;50:1115-22.
Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res 2004;30:261-77.
Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect 2020;50:332-4.
Smilowitz NR, Kunichoff D, Garshick M, Shah B, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J 2021;42:2270-9.
Sahu BR, Kampa RK, Padhi A, Panda AK. C-reactive protein: a promising biomarker for poor prognosis in COVID-19 infection. Clin Chim Acta 2020;509:91-4.
Zhou YZ, Teng XB, Han MF, et al. The value of PCT, IL-6, and CRP in the early diagnosis and evaluation of COVID-19. Eur Rev Med Pharmacol Sci 2021;25:1097-100.
Mitaka C. Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome. Clin Chim Acta 2005;351:17-29.
Sun R-R, Lu L, Liu M, Cao Y, Li X-C, Liu H, et al. Biomarkers and heart disease. Eur Rev Med Pharmacol Sci 2014;18:2927-35.
Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-60.
Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997;17:1121-7.
Haverkate F, Thompson SG, Duckert F, et al. Haemostasis factors in angina pectoris; relation to gender, age and acute-phase reaction results of the ECAT Angina Pectoris Study Group. Thromb Haemost 1995;73:561-7.
Boroviczeny K-G, Bottiger LE, Chattis A, Dawson JB, Fukutake K, Gunz FW, Lewis SM, Rewald E, Roubicek M, Ruhenstroth-Bauer G, Westergren A. Reference method for the erythrocyte sedimentation rate (ESR) test on human blood. Br J Haematol 1973;24:671-3.
Abramson N. Rouleaux formation. Blood 2006;107:4205.
Weinstein A, Del Giudice J. The erythrocyte sedimentation rate - time honored and tradition bound. J Rheumatol 1994;21:1177-8.
Saleh A, George J, Faour M, et al. Serum biomarkers in periprosthetic joint infections. Bone Joint Res 2020;7:85-93.
Henry-Amar M, Friedman S, Hayat M, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med 1991;114:361-5.
Lluberas-Acosta G, Schumacher HR. Markedly elevated erythrocyte sedimentation rates: Consideration of clinical implications in a hospital population. Br J Clin Pract 1996;50:138-42.
Davies J. Procalcitonin. J Clin Pathol 2015;68:675-9.
Samsudin I, Vasikaran SD. Clinical utility and measurement of procalcitonin. Clin Biochem Rev 2017;38:59-68.
Hamade B, Huang DT. Procalcitonin: where are we now? Crit Care Clin 2020;36:23-40.
Müller B, White JC, Nylén ES, et al. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001;86:396-404.
Heidari-Beni F, Vahedian-Azimi A, Shojaei S, et al. The level of procalcitonin in severe COVID-19 patients: a systematic review and meta-analysis. AdvExpMed Biol2021;1321:277-86.
Meisner M, Tschaikowsky K, Hutzler A, Schick C, Schüttler J. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med 1998;24:680-4.
Mimoz O, Benoist JF, Edouard AR, et al. Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome. Intensive Care Med 1998;24:185-8.
Wolff M, Joly-Guillou ML. La procalcitonine (PCT): Un outil diagnostique et de stratégie thérapeutique. Rev Francoph Lab 2011;41:39-43.
Davis TME, Assicot M, Bohuon C, et al. Serum procalcitonin in acute malaria concentrations. Trans R Soc Trop Med Hyg 1994;88:670–1.
Eberhard OK, Langefeld I, Kuse ER, et al. Procalcitonin in the early phase after renal transplantation - will it add to diagnostic accuracy? Clin Transplant 1998;12:206-11.
Durnaś B, Wątek M, Wollny T, et al. Utility of blood procalcitonin concentration in the management of cancer patients with infections. OncoTargets Ther 2016;9:469-75.
Naramura T, Tanaka K, Inoue T, et al. New reference ranges of procalcitonin excluding respiratory failure in neonates. Pediatr Int 2020;62:1151-7.
Bianco B, François-Garret B, Butin M, et al. Procalcitonin in preterm neonates: a different threshold and prolonged interpretation. Front Pediatr 2021;9:1-8.
Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463-74.
Kishen A, Muralidharan NP. Role of cytokines in inflammation. Int J Pharmaceutical Res 2020;12:118-24.
Bartekova M, Radosinska J, Jelemensky M, Dhalla NS. Role of cytokines and inflammation in heart function during health and disease. Heart Fail Rev 2018;23:733-58.
Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci 2019;20:6008.
Sasaki K, Fujita I, Hamasaki Y, Miyazaki S. Differentiating between bacterial and viral infection by measuring both C-reactive protein and 2′-5′-oligoadenylate synthetase as inflammatory markers. J Infect Chemother 2002;8:76-80.
Eggimann P, Que YA, Rebeaud F. Measurement of pancreatic stone protein in the identification and management of sepsis. Biomark Med 2019;13:135-45.
Cui C, Fu M, Gao B. Procalcitonin and pancreatic stone protein function as biomarkers in early diagnosis of pediatric acute osteomyelitis. Med Sci Monit 2017;23:5211-7.
Klein HJ, Niggemann P, Buehler PK, et al. Pancreatic stone protein predicts sepsis in severely burned patients irrespective of trauma severity: a monocentric observational study. Ann Surg 2021;274:E1179-86.
Grulich PF, Stewart DH, Oberoi P, et al. Human cytokine assay products from meso scale discovery. MSD Cat 2021;1-10.
https://www.quanterix.com/simoa-technology/
https://www.bdbiosciences.com/en-au/products/reagents/immunoassays/cba
https://www.luminexcorp.com/xmap-technology/#instruments
Parsa SF, Vafajoo A, Rostami A, et al. Early diagnosis of disease using microbead array technology: a review. Anal Chim Acta 2018;1032:1-17.
Khan SS, Smith MS, Reda D, et al. Multiplex bead array assays for detection of soluble cytokines: Comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom 2004;61:35-9.
Richens JL, Urbanowicz RA, Metcalf R, et al. Quantitative validation and comparison of multiplex cytokine kits. J Biomol Screen 2010;15:562-8.